| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000022343 |
| Receipt No. | R000025755 |
| Official scientific title of the study | Optimization of intravenous vancomycin treatment schedule for pediatric population with Monte Carlo Simulation |
| Date of disclosure of the study information | 2016/05/19 |
| Last modified on | 2018/12/27 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Optimization of intravenous vancomycin treatment schedule for pediatric population with Monte Carlo Simulation | |
| Title of the study (Brief title) | Optimization of intravenous vancomycin treatment schedule for pediatric population with Monte Carlo Simulation | |
| Region |
|
|
| Condition | ||
| Condition | Patients under 18 years old who were administered intravenous vancomycin in Department of Pediatrics or Department of Pediatric Cardiology in our institute between April 1st 2011 and March 31st 2016. | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To determine the optimal treatment schedule of vancomycin for pediatric patients with Monte Carlo Simulation. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The proportion of the patients who achieved more than 400 of AUC/MIC in the present treatment strategy in our institute. |
| Key secondary outcomes | To compare the duration required for body temperature to be normalized between the populations with AUC/MIC above 400 and below 400.
With Monte Carlo simulation, we will optimize the treatment strategy of vancomycin so that more than 90% of the patients achieve AUC/MIC more than 400. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients who were administered intravenous vancomycin in Department of Pediatrics or Department of Pediatric Cardiology between April 1st 2011 and March 31st 2016.
Age under 18 years when vancomycin was initiated. Written informed consent is obtained. |
|||
| Key exclusion criteria | Patients with renal dysfunction.
Data unavailability exists. Lack of informed consent. |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Reo Tanoshima |
| Organization | Yokohama City University |
| Division name | Department of Pediatrics |
| Address | Fukuura 3-9, Kanazawa-ku, Yokohama, Kanagawa, Japan |
| TEL | (+81)45-787-2800 |
| tanotch@yokohama-cu.ac.jp | |
| Public contact | |
| Name of contact person | Reo Tanoshima |
| Organization | Yokohama City University |
| Division name | Department of Pediatrics |
| Address | Fukuura 3-9, Kanazawa-ku, Yokohama, Kanagawa, Japan |
| TEL | (+81)45-787-2800 |
| Homepage URL | |
| tanotch@yokohama-cu.ac.jp | |
| Sponsor | |
| Institute | Department of Pediatrics,
Yokohama City University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Department of Pediatrics,
Yokohama City University |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | Pediatric patients who were administered vancomycin between April 1st 2011 to March 31st 2016 in Department of Pediatrics or Department of Pediatric Cardiology. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000025755 |